SEAVI Advent Private Equity announces the 1st close of its latest fund - SEAVI Advent Equity VIII

May 2026

SEAVI Advent Private Equity has announced the 1st closing of its latest fund - SEAVI Advent Equity VIII, consisting of 2 sub-funds under its SEAVI Advent VCC.

The Fund's initial close was raised from high net-worth individuals, corporate institutions and family offices. SEAVI Advent's partners also made a strong commitment of US$3 million in the Fund.

SEAVI Advent will continue to reach out to existing and new investors, mostly based in Singapore, Hong Kong, Mainland China and Europe. The preceding SEAVI Advent Equity VII (Special Situation) Fund I was raised in 2021.

Continuing with the successful strategy of its predecessor funds, SEAVI Advent Equity VIII will principally focus on private equity investments in Greater China, Singapore, Malaysia, and selectively into S.E. Asia. The Fund will invest into 8 - 10 opportunities, mainly in high growth, profitable and pre-IPO/IPO companies. Sectors covered will include Technology (Internet, E-commerce & AI Application), Cleantech, Consumer, Healthcare and Advanced Manufacturing.

SEAVI Advent has a group of partners with many years of private equity experience, headed by Co-Managing Partners, Mr. Derrick Lee and Mr. Kevin Chan, who have worked together since the early 2000s. A dedicated team based in Hong Kong and Shanghai sources for investment opportunities in Mainland China and Hong Kong while the team based in Singapore searches for suitable deals in Singapore, Malaysia and the surrounding region. With deal operational experiences built up over the years, these teams will add value to portfolio companies through operational improvements, strategic repositioning and market expansion both domestically and internationally. The firm will also share its experience and assist the portfolio companies to list on the most suitable stock exchanges in Singapore, Malaysia, Mainland China, Hong Kong, or the United States.

“We are encouraged by the strong support received from investors, given the challenging fundraising environment” said SEAVI Advent’s Chief Investment Officer and Managing Partner, Mr. Kevin Chan. “We believe our geographical area of focus and an emphasis on downside protection for all our investments will continue to offer compelling investment opportunities given the high growth, entrepreneurial environment and SEAVI Advent’s proven track record in creating value both for our investees as well as for our investors.”

About SEAVI Advent Private Equity

SEAVI Advent Private Equity, is one of the first private equity and venture capital firms to operate in the Asia Pacific region. Since 1984, the firm has invested over US$600 million into more than 120 Asian companies, from growth to late stage, as well as buyout and control transactions.

With a proven track record that includes ranking fourth on Preqin’s Top 10 performance funds for its 2003/04 vintage, SEAVI Advent has been instrumental in delivering value to many of its portfolio companies, and has developed an extensive record of successful investments, which include Universal Health International Group (2211.HK), Hainan Shuangcheng Pharmaceutical Co. Ltd (002693.SZ), and Clarity Medical Group (1406.HK) in the healthcare sector; Weimob Inc. (2013.HK), Huitongda Network (9878.HK), and Sinofriends in the TMT sector; Tsaker New Energy (1986.HK), and Pengyao Group (300664.SZ) in the new energy & advanced manufacturing sector.

SEAVI Advent VIII Fund focuses exclusively on investments in non-controlling public securities and profitable late-stage private companies.